Navigation Links
Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Michael D. Taylor, Ph.D., has joined the company's board of directors. Dr. Taylor is president and chief executive officer of Ensemble Discovery Corporation, a Cambridge, Massachusetts-based biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry(TM) (DPC(TM)) platform.

"Mike is a terrific addition to our board," said Cequent President and CEO, Peter Parker. "With more than 20 years in the pharmaceutical industry, his extensive experience ranges from drug discovery -- leading early and late-stage development projects across multiple therapeutic areas, including Lipitor(R) and Neurontin(R) -- to licensing, business development, and managing R&D alliances with pharmaceutical and biotech partners. His counsel and strong industry relationships will be valuable assets to Cequent as we continue to move our clinical candidates from pre-clinical development toward a successful IND submission with the FDA."

Dr. Taylor joined Ensemble Discovery Corporation in July of 2007. Previously, he was senior vice president for Pfizer's Global R&D division. In addition to his R&D experience, he is active in investor development, government affairs, and public policy affecting the pharmaceutical industry. Until 2003, he was adjunct professor of medicinal chemistry at the College of Pharmacy at the University of Michigan, where he was active in teaching medicinal chemistry and biopharmaceutics. Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts, and holds six patents.

Dr. Taylor has a doctorate in medicinal chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. For more information, visit

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):